Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study. Meeting Abstract

International Collaboration

cited authors

  • Pal, Sumanta Kumar; Grivas, Petros; Gupta, Shilpa; Valderrama, Begona Perez; Rodriguez-Vida, Alejo; Roghmann, Florian; Sevillano, Elena; Matin, Surena F.; Loriot, Yohann; Sridhar, Srikala S.; Sonpavde, Guru P.; Fleming, Mark T.; Lerner, Seth P.; Bellmunt, Joaquim; Master, Viraj A.; Tripathi, Abhishek; Davis, Kim; Van Veenhuyzen, David Friedrich; Weng, Richard; Daneshmand, Siamak

Publication Date

  • February 1, 2024

webpage

published in

category

keywords

  • 2
  • 261-376
  • 261-492-199-2823
  • 261-492-3532-2370-7650-2454-5112
  • 261-492-3532-2370-7650-2700
  • 3
  • 3229
  • 38092-20390
  • 38092-23141
  • 4
  • 613-225-313

start page

  • 629

end page

  • 629

volume

  • 42

issue

  • 4_SUPPL